Overview

Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease

Status:
Not yet recruiting
Trial end date:
2024-02-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability of ALXN1820 SC (subcutaneous) in participants with SCD (Sickle Cell Disease).
Phase:
Phase 2
Details
Lead Sponsor:
Alexion Pharmaceuticals